Tools
Familial Combined Hyperlipidemia
Introduction
Familial combined hyperlipidemia (FCH) is a common and prevalent hereditary lipid disorder. The inherited primary dyslipidemia is named after its variable expression of increased plasma cholesterol and triglyceride levels, which affects at least two family members.[1] In 1973, FCH was initially described as an autosomal dominant inherited lipid disorder by Goldstein et al, Rose et al, and Nikkila et al. However, it was later found to have a multigenic mode and complex inheritance.[2][3]
FCH manifests as increased serum cholesterol levels (hypercholesterolemia) and/or increased triglycerides (hypertriglyceridemia).[4] It may also present as isolated increases in apolipoprotein B (apoB) with a serum lipid profile in the reference range.[4] The estimated prevalence of FCH is approximately 0.5 to 4%.[5] The genetic element of FCH has not been fully understood to date.[6] Associated metabolic dysfunction includes increased very low-density lipoprotein (VLDL) and slowed removal of low-density (LDL) and triglyceride-rich lipoproteins.[6]
The abnormal increases in plasma lipids and triglycerides are significant risk factors for cardiovascular disease (CVD) and CVD-related mortality. The risk for mortality increases in individuals with underlying metabolic comorbidities such as type 2 diabetes (T2DM), obesity, alcohol dependence, hypothyroidism, and liver disease.[4] FCH is most commonly seen as an underlying risk factor in individuals with coronary heart disease and patients with acute myocardial infarction.[7]
The management of FCH patients includes therapeutic agents to lower cholesterol and triglyceride levels to prevent cardiovascular disease. FDA-approved treatments include HMG-CoA reductase inhibitors (statins), fibric acid derivatives (fibrates), bile acid sequestrants, PCSK9 inhibitors, niacin, and ezetimibe.[8][9] Other treatment options include omega-3 fatty acids (fish oil) and MTTP inhibitors (lomitapide).
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
As previously stated, the genetic element of FCH has not been fully understood to date.[6] The pattern of inheritance of FCH was initially reported to be autosomal dominant in 1973 by Goldstein et al.[2] Later research specified and proposed that FCH be familial or nonfamilial, making it a multigenic mode and complex inheritance.[2][3]
Alongside the hereditary aspect of FCH, other risk factors contributing to the pathogenesis include environmental elements.[3] The pathophysiologic mechanisms of FCH result in metabolic dysfunction, causing increased very low-density lipoprotein (VLDL), slowed removal of low-density (LDL) and triglyceride-rich lipoproteins, and unregulated overproduction of apo-B lipoproteins in the liver.[6][3]
Epidemiology
The estimated prevalence of FCH is approximately 0.5% to 4%.[5] Roughly 10% to 20% of individuals who have experienced premature myocardial infarction are found to have familial combined hyperlipidemia.[10] According to a study conducted by Paramsothy et al in 2009, the prevalence of combined hyperlipidemia demonstrates variation among different racial groups. The study found that Hispanics exhibited higher rates of combined hyperlipidemia compared to whites. Conversely, African-Americans had lower rates of combined hyperlipidemia than whites, despite having higher body mass index levels and abdominal adiposity. This suggests that African-Americans have lower odds of developing combined hyperlipidemia when compared to individuals of white ethnicity.[11]
Pathophysiology
Familial combined hyperlipidemia is believed to be caused by an underlying pathophysiological mechanism characterized by hepatic overproduction of lipoprotein particles containing apoB-100, namely VLDL and LDL. This results in elevated levels of plasma total cholesterol, triglycerides, and apoB. Furthermore, individuals with FCH exhibit reduced HDL cholesterol levels and an increase in small dense LDL (sdLDL) and remnant lipoprotein particles.[12]
Initially, it was believed that FCH was inherited through a dominant monogenic manner. However, subsequent studies proposed a more complex polygenic inheritance to explain the variability in the lipid phenotype. Several loci, specifically at 9p, 16q, and 11q, have been linked to LDL size in FCH patients.[13] Notably, the gene encoding Upstream Transcription Factor 1 (USF1) has been associated with FCH. USF1 regulates various genes related to glucose and lipid metabolism.[14][15]
Patients with FCH are noted to have delayed clearance of chylomicron and VLDL remnants.[16] One of the genes involved in their clearance pathways is the LPL gene.[17] A recent study has linked a mutation that substitutes aspartic acid with asparagine at position 151 in the LPL gene to an increased incidence of FCH.[18]
Impairment in the low-density lipoprotein receptor (LDLR) can increase LDL levels. Mutations in the LDLR may lead to FCH.[19] Proprotein convertase subtilisin kexin type 9 (PCSK9) is associated with the cholesterol synthesis markers lathosterol and desmosterol. PSCK9 levels are also a stimulus for LDLR degradation. A study by Brouwers et al demonstrated that PCSK9 levels are heritable and increased in patients with FCH.[20]
History and Physical
Patients with familial combined hyperlipidemia often have a family history of dyslipidemia, premature cardiovascular disease, and premature death from heart disease or stroke. Aside from the positive familial history, FCH patients may exhibit symptoms such as chest discomfort, difficulty breathing, or leg pain while walking. Additionally, they may possess risk factors for cardiovascular conditions, such as hypertension, diabetes, and obesity.[21]
FCH is a complex disorder with variable expression and penetrance, and the age of onset and severity of symptoms can differ among affected individuals within the same family. Therefore, obtaining a detailed family history of hyperlipidemia, cardiovascular disease, and premature death is crucial, especially among first-degree relatives.
The physical examination of a patient with FCH is typically unremarkable, with no specific physical findings associated with the disorder. However, patients with FCH may have signs of cardiovascular disease such as hypertension, peripheral arterial disease (PAD), or carotid bruits. Though they are rare in patients with FCH, a careful examination of the skin may reveal the presence of xanthomas. These cholesterol deposits are often associated with high cholesterol levels or triglycerides in the blood. They may indicate an underlying metabolic disorder such as familial combined hyperlipidemia or familial hypercholesterolemia.[22][23]
Furthermore, a comprehensive cardiac assessment may detect the existence of a murmur, indicating potential valvular heart disease, or indications of heart failure, such as peripheral edema, jugular venous distension, and hepatomegaly. A neurological examination may reveal the presence of focal deficits, suggesting cerebrovascular disease.
Evaluation
Familial combined hyperlipidemia can present with varying laboratory findings in different individuals and members of the same family. The laboratory results may reveal elevated levels of serum triglycerides, total cholesterol, mixed triglycerides, increased very-low-density lipoproteins (VLDLs), increased low-density lipoproteins (LDLs), raised levels of apolipoprotein B (apo-B), or reduced levels of high-density lipoprotein (HDL).[7] Elevations in triglycerides and apo-B may exhibit values of 1.5 mmol/L and 1.2 g/L, respectively.[1]
Several studies have reported an association between FCH and increased carotid intima-media thickness (IMT), a marker of subclinical atherosclerosis. Therefore, a carotid ultrasound may be performed to assess the presence of subclinical atherosclerosis in patients with FCH.[24][25]
Treatment / Management
Familial combined hyperlipidemia, the most commonly reported genetic dyslipidemia, increases the risk of early atherosclerosis expression.[1] The management of FCH surrounds reducing the increased lipid levels in circulation within the reference range and routine monitoring to decrease premature cardiovascular disease. The management of FCH is similar to other dyslipidemias, which include pharmacologic therapies and lifestyle changes such as diet and exercise.[26]
FDA-approved treatments include HMG-CoA reductase inhibitors (statins), fibric acid derivatives (fibrates), bile acid sequestrants, PCSK9 inhibitors, adenosine triphosphate-citrate lyase inhibitors (bempedoic acid), niacin and ezetimibe.[8][9] Other treatment options include omega-3 fatty acids (fish oil) and MTTP inhibitors (lomitapide).
Statins
- Atorvastatin
- Fluvastatin
- Lovastatin
- Pravastatin
- Rosuvastatin
- Simvastatin
- Pitavastatin[27]
Statins exert their mechanism of action by inhibiting the HMG-CoA reductase enzyme in the hepatocytes, further causing the decreased intracellular synthesis of cholesterol. HMG-CoA reductase is the rate-limiting step in the mevalonate pathway responsible for cholesterol synthesis.[28] The hepatic LDL receptors have a high affinity for LDL and VLDL particles, further causing endocytosis in the liver. Following binding, the cholesterol is mixed with bile salts and excreted as a waste product or recycled, reducing circulating serum cholesterol.
The majority of cholesterol in circulation is produced by internal hepatic synthesis relative to dietary intake, making statins a prevalently used agent in hyperlipidemia and dyslipidemia. The primary therapeutic goal of statins is to lower levels of low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein cholesterol (VLDL-C), triglycerides (TG), apolipoprotein B (apo-B) lipoprotein, and total cholesterol, while simultaneously increasing levels of high-density lipoprotein cholesterol (HDL-C).[27]
Fibrates
- Gemfibrozil
- Fenofibrate
- Fenofibric acid[29]
Fibric acids exert mechanistic effects by stimulating peroxisome proliferator-activated alpha (PPAR-a) receptors. Following the binding of the ligand to its target transcriptional factor PPAR-a receptors, it further causes downstream effects and activation of multiple biological processes. The therapeutic action of fibrates is mainly through the beta-oxidation of fatty acids and the metabolism of lipids in circulation, making it effective in hypercholesterolemia and hypertriglyceridemia. This further reduces TG particles and aids in the breakdown of VLDL. This helps decrease the atherosclerotic burden and plaque buildup in coronary vessels from dyslipidemias, further reducing CHD incidence.[29][30]
Bile Acid Sequesterants[31]
- Cholestyramine
- Colestipol
- Colesevelam
Bile acid sequestrants exert their mechanistic effects by decreasing LDL-C absorption in the gastrointestinal tract, further causing its excretion in feces. The sequestrants create an insoluble complex that is not digestible or can be reabsorbed, further depleting bile acids from circulation. The excretion of bile acids initiates more cholesterol in the liver to be converted to bile acids, upregulating LDL receptors in the liver and decreasing plasma LDL-C in circulation.[31]
PCSK9 Inhibitors
- Evolocumab
- Alirocumab
- Inclisiran[32]
Proprotein convertase subtilisin/Kexin type 9 (PCSK9) is a vital regulator of cholesterol. Mutations in PCSK9 result in a gain of function action, further increasing cholesterol in circulation and etiology for autosomal dominant familial hypercholesterolemia. PCSK9 inhibitors exert their mechanism of action by inhibiting PCSK9 receptors, which reduce LDL-C. The role of PCSK9 is to inhibit LDL receptor recycling which further increases LDL-C in circulation.
Inhibiting the PCSK9 protein halts the inhibitory LDL receptor recycling effect, increasing hepatic LDL receptors, further increasing cholesterol uptake from circulation, and decreasing plasma LDL-C levels. When patients fail to achieve LDL-C targets despite receiving statin and ezetimibe therapy at maximum doses, PCSK9 inhibitors should be considered an additional treatment option.[33][32][34]
Adenosine Triphosphate-citrate Lyase (ACL) Inhibitor
- Bempedoic acid[35]
Bemploic acid exerts its mechanism of action by inhibiting adenosine triphosphate-citrate lyase. The agent is a prodrug that acts in the liver once recognized by the enzyme acyl-CoA-synthetase-1 and converted to its active form, bempedoyl-CoA, further inhibiting ACL. It is FDA approved for heterozygous familial hypercholesterolemia and patients with ASVD who require additional management for decreasing LDL-C.[35]
Others
- Niacin
- Ezetimibe
- Omega-3 fatty acids (fish oil)
- Lomitapide
Differential Diagnosis
Familial combined hyperlipidemia has a broad range of differential diagnoses, as many hereditary and non-genetic etiologies cause increases in serum lipids.[26]
Genetic dyslipidemias include:
- Familial hypercholesterolemia
- Abetalipoproteinemia.
- Hypobetalipoproteinemia.
- Chylomicron retention disease
- Hypertriglyceridemia
FCH may present with more subordinate total serum cholesterol levels and LDL-C than familial hypercholesterolemia.[1] This may be due to the complete expression of FCH transpiring in adulthood. However, the risk of early onset of atherosclerosis is equivalent in both dyslipidemias. Early onset atherosclerosis is multifactorial when considering lipid and non-lipid characteristics such as insulin resistance and inadequate glucose metabolism, fatty liver, HTN, increased uric acid levels, and increased inflammatory markers in circulation.
Prognosis
The prognosis of FCH depends on several factors, including the age of onset, the severity of lipid abnormalities, comorbidities, and treatment adherence. FCH is associated with an increased risk of premature atherosclerotic cardiovascular disease (ASCVD), leading to significant morbidity and mortality if left untreated.
To date, no appropriately designed trials have been conducted to determine the unique risk of cardiovascular disease among patients with familial combined hyperlipidemia. However, some authors propose that their risk may be at least as high as that of patients with heterozygous familial hypercholesterolemia.[36]
Complications
Atherosclerosis
Familial combined hyperlipidemia is linked to a higher likelihood of developing atherosclerosis. While some patients may not experience any symptoms, evaluating the intima-media thickness of the common carotid artery can serve as a means of estimating the risk.[37]
Coronary Artery Disease
A significant association exists between familial combined hyperlipidemia and an elevated coronary artery disease (CAD) risk.[36][38] Notably, males with familial combined hyperlipidemia exhibit a higher prevalence of CAD than females, irrespective of their lipid profiles and other risk factors.[39]
Myocardial Infarction
Familial combined hyperlipidemia ranks high among the common causes of myocardial infarction in young people. In a study by Wiesbauer et al, the prevalence of FCH was 38% among patients younger than 40.[40]
Deterrence and Patient Education
Physicians should explain the genetic basis of FCH and how it is inherited in families. By understanding the genetic basis of the condition, patients can better understand their risk of developing cardiovascular disease and the importance of early intervention. In addition to genetic counseling, patients should be educated on lifestyle modifications that can help manage FCH. This includes proper diet, regular exercise, and weight management. In addition, other modifiable risk factors should be addressed, such as smoking cessation, alcohol consumption, and stress management.
Furthermore, medications may be prescribed to help reduce cholesterol levels and decrease heart disease risk in patients with FCH. It is essential to discuss medication use's potential benefits and risks with their patients and monitor for any adverse effects. Regular follow-up appointments should be scheduled to monitor the patient's progress and adjust the treatment plan. Ongoing support and education help patients manage FCH effectively and maintain their overall health.
Enhancing Healthcare Team Outcomes
FCH is an inherited disorder characterized by abnormal lipid accumulation in the circulation, which can lead to cardiovascular disease and associated complications. Effective management of FCH requires close communication and care coordination among the interprofessional healthcare team, including the primary care clinician, cardiologist, nurse, pharmacist, and mid-level providers.
As part of preventive care, the primary care team should conduct lipid screening to evaluate serum cholesterol levels in accordance with the guidelines provided by the United States Preventive Services Task Force (USPSTF). Additionally, they should assess contributing risk factors for coronary artery disease (CAD) and myocardial infarction, such as hypertension and diabetes. Earlier screening and diagnostic assessments may be warranted in patients at higher risk or with a family history of FCH. Comprehensive patient history should also be obtained, focusing on familial dyslipidemias or family history of heart disease.
The primary care provider should discuss preventative measures and healthy lifestyle strategies with patients, including weight loss, dietary modifications, smoking cessation, alcohol use, and routine exercise. Early goal-directed therapy with first-line statin treatment is recommended for patients with FCH. Patients with uncontrolled hyperlipidemia and underlying comorbidities, such as prior CAD, hypertension, and diabetes, who are at risk for adverse cardiovascular events, may benefit from specialty care provided by cardiologists or endocrinologists for a more comprehensive management plan.[41]
Patient education on FCH is an essential responsibility of the interprofessional team, including primary care providers, specialists, and healthcare professionals such as advanced practice practitioners. This education aims to enhance patient understanding of the disease, improve communication between patients and healthcare providers, and ensure continuity of care, leading to improved outcomes for individuals with genetic dyslipidemia.
References
Vaverková H, Karásek D. [Familial combined hyperlipidemia - the most common genetic dyslipidemia in population and in patients with premature atherothrombotic cardiovascular disease]. Vnitrni lekarstvi. 2018 Winter:64(1):25-29 [PubMed PMID: 29498872]
Veerkamp MJ, de Graaf J, Bredie SJ, Hendriks JC, Demacker PN, Stalenhoef AF. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arteriosclerosis, thrombosis, and vascular biology. 2002 Feb 1:22(2):274-82 [PubMed PMID: 11834528]
Taghizadeh E, Mardani R, Rostami D, Taghizadeh H, Bazireh H, Hayat SMG. Molecular mechanisms, prevalence, and molecular methods for familial combined hyperlipidemia disease: A review. Journal of cellular biochemistry. 2019 Jun:120(6):8891-8898. doi: 10.1002/jcb.28311. Epub 2018 Dec 16 [PubMed PMID: 30556165]
Bello-Chavolla OY, Kuri-García A, Ríos-Ríos M, Vargas-Vázquez A, Cortés-Arroyo JE, Tapia-González G, Cruz-Bautista I, Aguilar-Salinas CA. FAMILIAL COMBINED HYPERLIPIDEMIA: CURRENT KNOWLEDGE, PERSPECTIVES, AND CONTROVERSIES. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion. 2018:70(5):224-236. doi: 10.24875/RIC.18002575. Epub [PubMed PMID: 30307446]
Level 3 (low-level) evidenceTrinder M, Vikulova D, Pimstone S, Mancini GBJ, Brunham LR. Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia. Atherosclerosis. 2022 Jan:340():35-43. doi: 10.1016/j.atherosclerosis.2021.11.032. Epub 2021 Dec 6 [PubMed PMID: 34906840]
Taghizadeh E, Esfehani RJ, Sahebkar A, Parizadeh SM, Rostami D, Mirinezhad M, Poursheikhani A, Mobarhan MG, Pasdar A. Familial combined hyperlipidemia: An overview of the underlying molecular mechanisms and therapeutic strategies. IUBMB life. 2019 Sep:71(9):1221-1229. doi: 10.1002/iub.2073. Epub 2019 Jul 4 [PubMed PMID: 31271707]
Level 3 (low-level) evidenceGaddi A, Cicero AF, Odoo FO, Poli AA, Paoletti R, Atherosclerosis and Metabolic Diseases Study Group. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vascular health and risk management. 2007:3(6):877-86 [PubMed PMID: 18200807]
Singh G, Correa R. Fibrate Medications. StatPearls. 2023 Jan:(): [PubMed PMID: 31613536]
Pahan K. Lipid-lowering drugs. Cellular and molecular life sciences : CMLS. 2006 May:63(10):1165-78 [PubMed PMID: 16568248]
Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. The Journal of clinical investigation. 1973 Jul:52(7):1544-68 [PubMed PMID: 4718953]
Paramsothy P, Knopp R, Bertoni AG, Tsai MY, Rue T, Heckbert SR. Combined hyperlipidemia in relation to race/ethnicity, obesity, and insulin resistance in the Multi-Ethnic Study of Atherosclerosis. Metabolism: clinical and experimental. 2009 Feb:58(2):212-9. doi: 10.1016/j.metabol.2008.09.016. Epub [PubMed PMID: 19154954]
van Himbergen TM, Otokozawa S, Matthan NR, Schaefer EJ, Buchsbaum A, Ai M, van Tits LJ, de Graaf J, Stalenhoef AF. Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway. Arteriosclerosis, thrombosis, and vascular biology. 2010 Jan:30(1):113-20. doi: 10.1161/ATVBAHA.109.196550. Epub 2009 Oct 15 [PubMed PMID: 19834104]
Badzioch MD, Igo RP Jr, Gagnon F, Brunzell JD, Krauss RM, Motulsky AG, Wijsman EM, Jarvik GP. Low-density lipoprotein particle size loci in familial combined hyperlipidemia: evidence for multiple loci from a genome scan. Arteriosclerosis, thrombosis, and vascular biology. 2004 Oct:24(10):1942-50 [PubMed PMID: 15331429]
Pajukanta P, Lilja HE, Sinsheimer JS, Cantor RM, Lusis AJ, Gentile M, Duan XJ, Soro-Paavonen A, Naukkarinen J, Saarela J, Laakso M, Ehnholm C, Taskinen MR, Peltonen L. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nature genetics. 2004 Apr:36(4):371-6 [PubMed PMID: 14991056]
Level 3 (low-level) evidenceTaghizadeh E, Mirzaei F, Jalilian N, Ghayour Mobarhan M, Ferns GA, Pasdar A. A novel mutation in USF1 gene is associated with familial combined hyperlipidemia. IUBMB life. 2020 Apr:72(4):616-623. doi: 10.1002/iub.2186. Epub 2019 Nov 14 [PubMed PMID: 31725952]
Castro Cabezas M, de Bruin TW, de Valk HW, Shoulders CC, Jansen H, Willem Erkelens D. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. The Journal of clinical investigation. 1993 Jul:92(1):160-8 [PubMed PMID: 8100834]
Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, Pramstaller PP, Penninx BW, Janssens AC, Wilson JF, Spector T, Martin NG, Pedersen NL, Kyvik KO, Kaprio J, Hofman A, Freimer NB, Jarvelin MR, Gyllensten U, Campbell H, Rudan I, Johansson A, Marroni F, Hayward C, Vitart V, Jonasson I, Pattaro C, Wright A, Hastie N, Pichler I, Hicks AA, Falchi M, Willemsen G, Hottenga JJ, de Geus EJ, Montgomery GW, Whitfield J, Magnusson P, Saharinen J, Perola M, Silander K, Isaacs A, Sijbrands EJ, Uitterlinden AG, Witteman JC, Oostra BA, Elliott P, Ruokonen A, Sabatti C, Gieger C, Meitinger T, Kronenberg F, Döring A, Wichmann HE, Smit JH, McCarthy MI, van Duijn CM, Peltonen L, ENGAGE Consortium. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nature genetics. 2009 Jan:41(1):47-55. doi: 10.1038/ng.269. Epub 2008 Dec 7 [PubMed PMID: 19060911]
Level 2 (mid-level) evidenceTaghizadeh E, Ghayour-Mobarhan M, Ferns GA, Pasdar A. A novel variant in LPL gene is associated with familial combined hyperlipidemia. BioFactors (Oxford, England). 2020 Jan:46(1):94-99. doi: 10.1002/biof.1570. Epub 2019 Oct 10 [PubMed PMID: 31599081]
Civeira F, Jarauta E, Cenarro A, García-Otín AL, Tejedor D, Zambón D, Mallen M, Ros E, Pocoví M. Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting. Journal of the American College of Cardiology. 2008 Nov 4:52(19):1546-53. doi: 10.1016/j.jacc.2008.06.050. Epub [PubMed PMID: 19007590]
Level 2 (mid-level) evidenceBrouwers MC, Konrad RJ, van Himbergen TM, Isaacs A, Otokozawa S, Troutt JS, Schaefer EJ, van Greevenbroek MM, Stalenhoef AF, de Graaf J. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2013 Nov:23(11):1115-21. doi: 10.1016/j.numecd.2012.11.008. Epub 2013 Jan 18 [PubMed PMID: 23333725]
Level 2 (mid-level) evidenceCarr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. The Journal of clinical endocrinology and metabolism. 2004 Jun:89(6):2601-7 [PubMed PMID: 15181030]
Maharaj S, Chang S, Nayak SB. Familial hypercholesterolemia presenting with multiple nodules of the hands and elbow. Clinical case reports. 2015 Jun:3(6):411-4. doi: 10.1002/ccr3.249. Epub 2015 Apr 9 [PubMed PMID: 26185639]
Level 3 (low-level) evidenceZak A, Zeman M, Slaby A, Vecka M. Xanthomas: clinical and pathophysiological relations. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2014 Jun:158(2):181-8. doi: 10.5507/bp.2014.016. Epub 2014 Apr 29 [PubMed PMID: 24781043]
Junyent M, Zambón D, Gilabert R, Cofán M, Núñez I, Ros E. Carotid atherosclerosis in familial combined hyperlipidemia associated with the APOB/APOA-I ratio. Atherosclerosis. 2008 Apr:197(2):740-6 [PubMed PMID: 17698072]
Level 2 (mid-level) evidenceKeulen ET, Kruijshoop M, Schaper NC, Hoeks AP, de Bruin TW. Increased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein B. Arteriosclerosis, thrombosis, and vascular biology. 2002 Feb 1:22(2):283-8 [PubMed PMID: 11834529]
Level 1 (high-level) evidenceParhofer KG. The Treatment of Disorders of Lipid Metabolism. Deutsches Arzteblatt international. 2016 Apr 15:113(15):261-8. doi: 10.3238/arztebl.2016.0261. Epub [PubMed PMID: 27151464]
Bansal AB, Cassagnol M. HMG-CoA Reductase Inhibitors. StatPearls. 2023 Jan:(): [PubMed PMID: 31194369]
Tricarico PM, Crovella S, Celsi F. Mevalonate Pathway Blockade, Mitochondrial Dysfunction and Autophagy: A Possible Link. International journal of molecular sciences. 2015 Jul 15:16(7):16067-84. doi: 10.3390/ijms160716067. Epub 2015 Jul 15 [PubMed PMID: 26184189]
Mathew CT, Singh P. Fibric Acid Antilipemic Agents. StatPearls. 2023 Jan:(): [PubMed PMID: 30860743]
Shepherd J. Mechanism of action of fibrates. Postgraduate medical journal. 1993:69 Suppl 1():S34-41 [PubMed PMID: 8497455]
Lent-Schochet D, Jialal I. Antilipemic Agent Bile Acid Sequestrants. StatPearls. 2023 Jan:(): [PubMed PMID: 31751096]
Pokhrel B, Yuet WC, Levine SN. PCSK9 Inhibitors. StatPearls. 2023 Jan:(): [PubMed PMID: 28846236]
Tomlinson B, Patil NG, Fok M, Lam CWK. Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia. Endocrinology and metabolism (Seoul, Korea). 2021 Apr:36(2):279-295. doi: 10.3803/EnM.2021.964. Epub 2021 Apr 19 [PubMed PMID: 33866776]
Handelsman Y, Lepor NE. PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. Journal of the American Heart Association. 2018 Jun 22:7(13):. doi: 10.1161/JAHA.118.008953. Epub 2018 Jun 22 [PubMed PMID: 29934421]
Markham A. Bempedoic Acid: First Approval. Drugs. 2020 May:80(7):747-753. doi: 10.1007/s40265-020-01308-w. Epub [PubMed PMID: 32314225]
Skoumas I, Masoura C, Pitsavos C, Tousoulis D, Papadimitriou L, Aznaouridis K, Chrysohoou C, Giotsas N, Toutouza M, Tentolouris C, Antoniades C, Stefanadis C. Evidence that non-lipid cardiovascular risk factors are associated with high prevalence of coronary artery disease in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia. International journal of cardiology. 2007 Oct 1:121(2):178-83 [PubMed PMID: 17188767]
Level 2 (mid-level) evidenceHalenka M, Vaverkova H, Hutyra M, Karasek D, Slavik L, Novotny D, Krskova M. Detection of early atherosclerosis using the ultrasound parameter of the intima-media thickness of the common carotid artery in families with familial combined hyperlipidemia. International angiology : a journal of the International Union of Angiology. 2004 Sep:23(3):230-7 [PubMed PMID: 15765037]
Level 2 (mid-level) evidenceVoors-Pette C, de Bruin TW. Excess coronary heart disease in Familial Combined Hyperlipidemia, in relation to genetic factors and central obesity. Atherosclerosis. 2001 Aug:157(2):481-9 [PubMed PMID: 11472750]
Pitsavos C, Skoumas I, Masoura C, Aznaouridis K, Papadimitriou L, Chrysohoou C, Giotsas N, Toutouza M, Stefanadis C. Prevalence and determinants of coronary artery disease in males and females with familial combined hyperlipidaemia. Atherosclerosis. 2008 Aug:199(2):402-7. doi: 10.1016/j.atherosclerosis.2007.11.021. Epub 2007 Dec 27 [PubMed PMID: 18164018]
Wiesbauer F, Blessberger H, Azar D, Goliasch G, Wagner O, Gerhold L, Huber K, Widhalm K, Abdolvahab F, Sodeck G, Maurer G, Schillinger M. Familial-combined hyperlipidaemia in very young myocardial infarction survivors ({ or =40 years of age). European heart journal. 2009 May:30(9):1073-9. doi: 10.1093/eurheartj/ehp051. Epub 2009 Mar 10 [PubMed PMID: 19276196]
Helfand M, Carson S. Screening for Lipid Disorders in Adults: Selective Update of 2001 US Preventive Services Task Force Review. 2008 Jun:(): [PubMed PMID: 20722146]